AGNPF - Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial CEO Clips Video
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke.
If you cannot view the video above, please visit:
https://www.b-tv.com/post/cse-agn-algernon-pharmaceuticals-advancing-dmt-into-a-phase-1-clinical-trial-btv-ceo-clips-60sec
Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF)
https://algernonpharmaceuticals.com/
About CEO Clips:
CEO Clips – are short company video profiles broadcast to a large audience of investors on TV and 15+ financial sites including Reuters, Yahoo!Finance, and Wall Street Journal.
BTV – Business Television/CEO Clips
Discover Companies to Invest in
Contact: Trina Schlingmann (604) 664-7401 x 5 trina@b-tv.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/143122
| Company Name: | Algernon Pharmaceuticals Inc - Class A |
| Stock Symbol: | AGNPF |
| Market: | OTC |
| Website: | algernonpharmaceuticals.com |
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by Newsfile via Quote Media. Read our full disclaimer.